Gotoh M., Matsuda J.Induction of anticardiolipin antibody and/or lupus anticoagulant in rabbits by immunization with lipoteichoic acid, lipopolysaccharide and lipid A. Lupus1996; 5: 593-597.
2.
Matsuda J. et al. Distinguishing β2-glycoprotein I dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. Br J Haematol1993 ; 85: 799-802.
3.
Exner T. et al. Guidelines for testing and revised criteria for lupus anticoagulants . Thromb Haemost1991; 65: 320-322.
4.
Matsuda J. et al. Anticoagulant activity of an anti-β2-glycoprotein I antibody is dependent on the presence of β2-glycoprotein I. Am J Hematol1993; 44: 187-191.
5.
Vaarala P., Vaara M., Palosuo T.Effective inhibition cardiolipin-binding antibodies in Gram-negative infections by bacterial lipopolysaccharide. Scand J Immunol1988; 28: 607-612.
6.
Facer CA, Angiostratidou G.High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria. Clin Exp Immunol1994; 95: 304-309.
7.
Manco-Johnson MJ et al. Lupus anticoagulant and protein S in children with postvaricella purpura fulminans or thrombosis. J Pediatr1996; 128: 319-323.
8.
Gotoh M., Matsuda J.Human immunodeficiency virus rather than hepatitis C virus infection is relevant to the development of an anticardiolipin antibody. Am J Hematol1995; 50: 220-222.
9.
Alving CRAntibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids1986; 40: 303-314.
